<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00361595</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446HUS120</org_study_id>
    <nct_id>NCT00361595</nct_id>
  </id_info>
  <brief_title>Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women</brief_title>
  <official_title>Open Label Proof of Concept Study of IV Zoledronic Acid (ZA) 5 mg After Forteo in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the adequacy of zoledronic acid in maintaining bone
      mass after two years of treatment with Forteo, in postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single center open label proof of concept study, recruiting subjects
      previously treated with Forteo for at least 12 months.

      A screening period of 3 to 6 weeks will precede the treatment period. At the baseline visit,
      patients whose eligibility is confirmed will be treated with ZA and followed for 12 months.
      Safety and efficacy will be assessed at regular intervals (day one, day 10, month 2, month 6,
      month 9 and month 12). Renal safety will be assessed prior to the i.v. dose of study
      medication, day 10 after the i.v. dose of study medication and at 12 months. Bone density at
      the lumbar spine (L1-4) and total hip will be performed at 6 months and at the end of the 12
      month treatment period. Biomarker analyses for secondary endpoint will be performed for at
      day 10, month 2, month 6, month 9 and month 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lumbar Spine BMD (Bone Mineral Density) in g/cm^2 From Baseline to Month 12 Relative to Baseline as Measured by DXA (Dual-energy X-ray Absorptiometry)</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Density (Grams/cm^2) at the Total Hip at 6 and 12 Months</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Change in bone density (grams/cm^2) at the total hip at 6 and 12 months. 12 month reported based on usual interval for bone density follow-up in clinical practice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum C-telopeptide Type 1 Collagen (CTX) (at Day 10 and Months 2, 6, 9 and 12)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in serum c-telopeptide type 1 collagen (CTX) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum N-propeptide Type 1 Collagen (P1NP) (at Day 10 and Months 2, 6, 9 and 12)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in serum n-propeptide type 1 collagen (P1NP) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg zoledronic acid in a single 15 minute IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>5 mg zoledronic acid administered in a single 15 minute IV</description>
    <arm_group_label>open label</arm_group_label>
    <other_name>zometa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women to age 85, inclusive

          -  Finish treatment of 12 months or longer with Forteo

          -  Signed informed consent prior to initiation of any study-mandated procedure.

        Exclusion Criteria:

          -  Hip and spine DXA T-score &gt;-1.0

          -  Patients with 25-(OH) vitamin D levels less than 15 ng/mL at Visit 1. (Patient can be
             repleted with vitamin D 50,000 units biweekly for up to 2 months and re-screened
             anytime during the 2 months while continuing Forteo.)

          -  Baseline renal insufficiency (calculated creatinine clearance less than 40.0 mL/min
             (MDRD) at Visit 1 and/or Visit 2 or urine dipstick greater than or equal to 2+ protein
             without evidence of contamination or bacteriuria (may be repeated one time at least a
             week apart if there is suspicion of contamination). Patients with calculated
             creatinine clearance equal to or greater than 40.0 mL/min and less than 60.0 mL/min or
             serum creatinine greater than the upper limit of normal at Visit 1 must be retested
             between Visit 1 and 2. Patients with calculated creatinine clearance greater than 60.0
             mL/min and serum creatinine within normal limits at Visit 1 do not require re-test.

          -  Patients who require re-test of creatinine clearance between Visit 1 and 2 will be
             excluded if there is an increase in serum creatinine greater than 0.5 mg/dL between
             Visit 1 and Visit 2.

          -  Serum calcium &lt;8.5 or &gt;11.0 mg/dl at Visit 1

          -  AST or ALT greater than twice the upper limit of normal

          -  Serum alkaline phosphatase greater than 1.5 times the upper limit of normal (liver
             fraction)

          -  No history of retinopathy or nephropathy especially in the presence of uncontrollable
             IDDM with Hb1 AC &gt; 10%

          -  Hypersensitivity to bisphosphonates

          -  Treatment with biphosphonates while on Forteo

          -  Prior treatment with i.v. biphosphonates

          -  Estrogen, calcitonin, raloxifene use prior to Forteo treatment are not exclusions, but
             concomitant therapy during with any bone agents during the trial will not be permitted

          -  Any prior use of strontium ranelate or sodium fluoride

          -  Chronic use of systemic corticosteroids (oral or i.v.) within the last year:

        NOTE: Use of corticosteroids in forms such as topical creams, nasal or inhaled formulations
        or those injected locally (intra-articularly) are NOT exclusionary.

          -  Prior exposure to anabolic steroids or growth hormone within 6 months prior to
             randomization

          -  Treatment with any investigational drug(s) and/or devices within 30 days prior to
             randomization.

          -  History of iritis or uveitis, except when secondary to trauma, and must have resolved
             for more than 2 years prior to randomization.

          -  Cancer exclusions:

               -  Patients with a new diagnosis or active treatment for any malignancy less than or
                  equal to 12 months prior to Visit 1.

               -  Patients with evidence of any metastases on or prior to randomization, or with a
                  history of metastases

               -  Subjects with evidence of paraneoplastic syndrome, especially those characterized
                  by hypercalcemia during screening or by history

               -  Patients with the following may be included: basal cell or squamous cell
                  carcinoma of the skin, colonic polyps with non-invasive malignancy which have
                  been removed, and Carcinoma in-situ (CIS) of the prostate (Stage I only) that has
                  been surgically removed.

          -  Previous major solid organ or bone marrow transplant recipient or on a transplant
             waiting list

          -  Any disease of the spine that would preclude the proper acquisition of a lumbar spine
             DXA (L1-L4) e.g., implantable devices, scoliosis, ankylosing spondylitis, DJD. (Less
             than two lumbar spine vertebral bodies evaluable)

          -  Active primary hyperparathyroidism or hypoparathyroidism

          -  Subject with complete thyroidectomy

          -  Active hyperthyroidism

          -  Hypothyroidism not treated with adequate replacement therapy

          -  History of multiple myeloma or Paget's disease

          -  Patients with severe dental problems or current dental infections, or with recent or
             impending dental surgery within three months of dosing

          -  Any medical or psychiatric condition which, in the opinion of the investigator, would
             preclude the participant from adhering to the protocol or completing the trial per
             protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Deal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2006</study_first_submitted>
  <study_first_submitted_qc>August 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2006</study_first_posted>
  <results_first_submitted>October 13, 2010</results_first_submitted>
  <results_first_submitted_qc>December 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2011</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Chad Deal, M.D.</investigator_full_name>
    <investigator_title>Chad Deal, M.D.</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>zoledronic acid</keyword>
  <keyword>forteo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment, 35 Subjects Start date: August, 2006 Completion date: April, 2008 Study took place at an academic medical center, recruiting subjects from investigator's practice.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Open Label</title>
          <description>5 mg zoledronic acid in a single 15 minute IV (intervenous)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label</title>
          <description>5 mg zoledronic acid in a single 15 minute IV (intervenous)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.8" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lumbar Spine BMD (Bone Mineral Density) in g/cm^2 From Baseline to Month 12 Relative to Baseline as Measured by DXA (Dual-energy X-ray Absorptiometry)</title>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>5 mg zoledronic acid in a single 15 minute IV (intervenous)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lumbar Spine BMD (Bone Mineral Density) in g/cm^2 From Baseline to Month 12 Relative to Baseline as Measured by DXA (Dual-energy X-ray Absorptiometry)</title>
          <units>grams/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread=".036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Density (Grams/cm^2) at the Total Hip at 6 and 12 Months</title>
        <description>Change in bone density (grams/cm^2) at the total hip at 6 and 12 months. 12 month reported based on usual interval for bone density follow-up in clinical practice.</description>
        <time_frame>6 months and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>5 mg zoledronic acid in a single 15 minute IV (intervenous)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Density (Grams/cm^2) at the Total Hip at 6 and 12 Months</title>
          <description>Change in bone density (grams/cm^2) at the total hip at 6 and 12 months. 12 month reported based on usual interval for bone density follow-up in clinical practice.</description>
          <units>grams/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread=".031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum C-telopeptide Type 1 Collagen (CTX) (at Day 10 and Months 2, 6, 9 and 12)</title>
        <description>Change in serum c-telopeptide type 1 collagen (CTX) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>5 mg zoledronic acid in a single 15 minute IV (intervenous)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum C-telopeptide Type 1 Collagen (CTX) (at Day 10 and Months 2, 6, 9 and 12)</title>
          <description>Change in serum c-telopeptide type 1 collagen (CTX) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.1" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum N-propeptide Type 1 Collagen (P1NP) (at Day 10 and Months 2, 6, 9 and 12)</title>
        <description>Change in serum n-propeptide type 1 collagen (P1NP) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>5 mg zoledronic acid in a single 15 minute IV (intervenous)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum N-propeptide Type 1 Collagen (P1NP) (at Day 10 and Months 2, 6, 9 and 12)</title>
          <description>Change in serum n-propeptide type 1 collagen (P1NP) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect.</description>
          <units>mcg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.2" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Open Label</title>
          <description>5 mg zoledronic acid in a single 15 minute IV (intervenous)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.8</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient increase in serum creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chad Deal</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-444-6575</phone>
      <email>dealc@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

